Materiały źródłowe

• #1 Prostate Cancer | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/prostate-cancer.html

  Metastatic prostate cancer is prostate cancer that has spread outside of the prostate to other parts of the body. This is also known as stage IV disease. […] We work together as a team of specialists to treat stage IV prostate cancer. Patients may receive: Hormone therapy, Chemotherapy, Radiation therapy, Supportive care. […] The average length of survival after a new, metastatic prostate cancer diagnosis is about 5 to 6 years. […] If a patient’s prostate cancer has spread beyond the prostate and the surrounding area, he is given systemic therapies like hormone therapy and possibly chemotherapy. While cancer responds to hormone therapy, it is called castrate-sensitive disease. Over time, the disease may become less responsive to hormone therapy and start growing again. This is called castrate-resistant disease. Patients with castrate-resistant disease can be treated with a number of additional therapies. Many are eligible for clinical trials with newer drugs or drug combinations, including immunotherapy.

• #2 What lifestyle changes can help me avoid prostate cancer? – Harvard Health

  https://www.health.harvard.edu/mens-health/what-lifestyle-changes-can-help-me-avoid-prostate-cancer

  If men live long enough, most will develop cancer cells in their prostate gland. About 80% of men ages 80 and older live with some prostate cancer. […] Therefore, the more important questions are what lifestyle changes might delay the onset of prostate cancer and decrease the risk of developing advanced prostate cancer. Here are three areas that observational studies have found may help. […] Research has shown that the same types of diets associated with better heart and brain health are linked to a reduced risk of aggressive prostate cancer. In a study published in the March 2022 issue of The American Journal of Clinical Nutrition, researchers who followed 47,239 men over 28 years found that men who reported eating primarily a plant-based diet, like the Mediterranean or DASH diets, had a significantly lower risk of developing aggressive prostate cancer.

• #3 Prostate Cancer Prevention – NCI

  https://www.cancer.gov/types/prostate/patient/prostate-prevention-pdq

  Avoiding risk factors and increasing protective factors may help prevent cancer. […] The following risk factors may increase the risk of prostate cancer: Age, Family history of prostate cancer, Race, Hormones, Vitamin E, Folic acid, Dairy and calcium. […] The following protective factors may decrease the risk of prostate cancer: Folate, Finasteride and dutasteride. […] Cancer prevention clinical trials are used to study ways to prevent cancer. […] New ways to prevent prostate cancer are being studied in clinical trials.

• #4 Prostate Cancer Prevention – NCI

  https://www.cancer.gov/types/prostate/patient/prostate-prevention-pdq

  Avoiding risk factors and increasing protective factors may help prevent cancer. […] The following risk factors may increase the risk of prostate cancer: Age, Family history of prostate cancer, Race, Hormones, Vitamin E, Folic acid, Dairy and calcium. […] The following protective factors may decrease the risk of prostate cancer: Folate, Finasteride and dutasteride. […] Cancer prevention clinical trials are used to study ways to prevent cancer. […] New ways to prevent prostate cancer are being studied in clinical trials.

• #5 What lifestyle changes can help me avoid prostate cancer? – Harvard Health

  https://www.health.harvard.edu/mens-health/what-lifestyle-changes-can-help-me-avoid-prostate-cancer

  If men live long enough, most will develop cancer cells in their prostate gland. About 80% of men ages 80 and older live with some prostate cancer. […] Therefore, the more important questions are what lifestyle changes might delay the onset of prostate cancer and decrease the risk of developing advanced prostate cancer. Here are three areas that observational studies have found may help. […] Research has shown that the same types of diets associated with better heart and brain health are linked to a reduced risk of aggressive prostate cancer. In a study published in the March 2022 issue of The American Journal of Clinical Nutrition, researchers who followed 47,239 men over 28 years found that men who reported eating primarily a plant-based diet, like the Mediterranean or DASH diets, had a significantly lower risk of developing aggressive prostate cancer.

• #6 Prostate Cancer Prevention – NCI

  https://www.cancer.gov/types/prostate/patient/prostate-prevention-pdq

  Avoiding risk factors and increasing protective factors may help prevent cancer. […] The following risk factors may increase the risk of prostate cancer: Age, Family history of prostate cancer, Race, Hormones, Vitamin E, Folic acid, Dairy and calcium. […] The following protective factors may decrease the risk of prostate cancer: Folate, Finasteride and dutasteride. […] Cancer prevention clinical trials are used to study ways to prevent cancer. […] New ways to prevent prostate cancer are being studied in clinical trials.

• #7 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  Approximately 1 in 10 men with advanced prostate cancer carries an inherited gene mutation. This can open a unique treatment toolbox to them, offer opportunities for leading-edge clinical trials and research, and may offer a potential lifesaving impact to their blood relatives. […] Nearly 12 percent of men with advanced prostate cancer carry inherited genes that increase their risk for faster-growing forms of the disease that are more likely to spread. Knowing whether you carry one of these genes may help your physician precisely tailor your prostate cancer treatment. […] You should consider genetic testing if you have metastatic prostate cancer. We also recommend genetic testing and counseling for men with prostate cancer who have: A family history of prostate cancer or several men in your family who have had it, One close family member who has had high-grade, advanced or metastatic prostate cancer, A family history of breast, ovarian or pancreatic cancer, A family member with a known genetic risk factor such as a mutation in BRCA1, BRCA2, ATM, CHEK2, etc.

• #8 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The potential harms of screening, diagnostic procedures, and treatment occur soon after screening takes place. […] The USPSTF strongly encourages research on screening for and treatment of prostate cancer in African American men. […] Studies are needed to confirm that African American men who undergo screening receive similar or greater reductions in prostate cancer mortality compared with men in the general population, as well as to explore the optimal screening frequency and whether beginning screening before age 55 years provides additional benefits in African American men. […] The USPSTF does not recommend screening for prostate cancer in men, including African American men, older than 70 years. […] The USPSTF believes that a reasonable approach for clinicians is to inform men with a family history of prostate cancer, particularly those with multiple first-degree relatives with prostate cancer, about their increased risk of developing cancer as well as the potential earlier age at disease onset. […] The USPSTF does not recommend screening for prostate cancer in men, including men with a family history of prostate cancer, older than 70 years.

• #9 Prostate Cancer Prevention – NCI

  https://www.cancer.gov/types/prostate/patient/prostate-prevention-pdq

  Avoiding risk factors and increasing protective factors may help prevent cancer. […] The following risk factors may increase the risk of prostate cancer: Age, Family history of prostate cancer, Race, Hormones, Vitamin E, Folic acid, Dairy and calcium. […] The following protective factors may decrease the risk of prostate cancer: Folate, Finasteride and dutasteride. […] Cancer prevention clinical trials are used to study ways to prevent cancer. […] New ways to prevent prostate cancer are being studied in clinical trials.

• #10 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  Approximately 1 in 10 men with advanced prostate cancer carries an inherited gene mutation. This can open a unique treatment toolbox to them, offer opportunities for leading-edge clinical trials and research, and may offer a potential lifesaving impact to their blood relatives. […] Nearly 12 percent of men with advanced prostate cancer carry inherited genes that increase their risk for faster-growing forms of the disease that are more likely to spread. Knowing whether you carry one of these genes may help your physician precisely tailor your prostate cancer treatment. […] You should consider genetic testing if you have metastatic prostate cancer. We also recommend genetic testing and counseling for men with prostate cancer who have: A family history of prostate cancer or several men in your family who have had it, One close family member who has had high-grade, advanced or metastatic prostate cancer, A family history of breast, ovarian or pancreatic cancer, A family member with a known genetic risk factor such as a mutation in BRCA1, BRCA2, ATM, CHEK2, etc.

• #11 How to Prevent Prostate Cancer? | Prostate Cancer Prevention | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/prevention.html

  There is no sure way to prevent prostate cancer. Many prostate cancer risk factors, such as age, race, and family history, cant be controlled. But there are some things you can do that might lower your risk of prostate cancer. […] Some studies have found that men with excess body weight have a higher risk of developing advanced prostate cancer or prostate cancer that is more likely to be fatal. […] Although not all studies agree, several have found a higher risk of prostate cancer in men whose diets are high in dairy products and calcium. […] For now, the best advice about diet and activity to possibly reduce the risk of prostate cancer is to: Get to and stay at a healthy weight. Be physically active. Follow a healthy eating pattern, which includes a variety of colorful fruits and vegetables and whole grains, and avoids or limits red and processed meats, sugar-sweetened beverages, and highly processed foods.

• #12 What lifestyle changes can help me avoid prostate cancer? – Harvard Health

  https://www.health.harvard.edu/mens-health/what-lifestyle-changes-can-help-me-avoid-prostate-cancer

  Maintaining a healthy weight and avoiding obesity is linked to a lower chance of developing advanced prostate cancer. Also, limiting meat and added sugars may be good for prostate health. […] Some evidence suggests that regular exercise can lower a man’s likelihood of getting prostate cancer. In 2019, Harvard researchers published findings that showed men who engaged most frequently in vigorous activity had a 30% lower risk of developing advanced prostate cancer and a 25% lower risk of dying from prostate cancer compared with men who exercised the least. […] Men who ejaculate frequently appear to have a lower risk of prostate cancer. According to one long-running large study, men who ejaculated more than 21 times per month had a 20% lower prostate cancer risk than those who ejaculated four to seven times monthly.

• #13 How to Prevent Prostate Cancer? | Prostate Cancer Prevention | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/prevention.html

  There is no sure way to prevent prostate cancer. Many prostate cancer risk factors, such as age, race, and family history, cant be controlled. But there are some things you can do that might lower your risk of prostate cancer. […] Some studies have found that men with excess body weight have a higher risk of developing advanced prostate cancer or prostate cancer that is more likely to be fatal. […] Although not all studies agree, several have found a higher risk of prostate cancer in men whose diets are high in dairy products and calcium. […] For now, the best advice about diet and activity to possibly reduce the risk of prostate cancer is to: Get to and stay at a healthy weight. Be physically active. Follow a healthy eating pattern, which includes a variety of colorful fruits and vegetables and whole grains, and avoids or limits red and processed meats, sugar-sweetened beverages, and highly processed foods.

• #14 What lifestyle changes can help me avoid prostate cancer? – Harvard Health

  https://www.health.harvard.edu/mens-health/what-lifestyle-changes-can-help-me-avoid-prostate-cancer

  If men live long enough, most will develop cancer cells in their prostate gland. About 80% of men ages 80 and older live with some prostate cancer. […] Therefore, the more important questions are what lifestyle changes might delay the onset of prostate cancer and decrease the risk of developing advanced prostate cancer. Here are three areas that observational studies have found may help. […] Research has shown that the same types of diets associated with better heart and brain health are linked to a reduced risk of aggressive prostate cancer. In a study published in the March 2022 issue of The American Journal of Clinical Nutrition, researchers who followed 47,239 men over 28 years found that men who reported eating primarily a plant-based diet, like the Mediterranean or DASH diets, had a significantly lower risk of developing aggressive prostate cancer.

• #15 What lifestyle changes can help me avoid prostate cancer? – Harvard Health

  https://www.health.harvard.edu/mens-health/what-lifestyle-changes-can-help-me-avoid-prostate-cancer

  Maintaining a healthy weight and avoiding obesity is linked to a lower chance of developing advanced prostate cancer. Also, limiting meat and added sugars may be good for prostate health. […] Some evidence suggests that regular exercise can lower a man’s likelihood of getting prostate cancer. In 2019, Harvard researchers published findings that showed men who engaged most frequently in vigorous activity had a 30% lower risk of developing advanced prostate cancer and a 25% lower risk of dying from prostate cancer compared with men who exercised the least. […] Men who ejaculate frequently appear to have a lower risk of prostate cancer. According to one long-running large study, men who ejaculated more than 21 times per month had a 20% lower prostate cancer risk than those who ejaculated four to seven times monthly.

• #16 Diet and prostate cancer | Prostate Cancer UK

  https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/your-diet-and-physical-activity/

  A healthy diet is important for general health and can help you stay a healthy weight. It can also help you manage the effects of prostate cancer and its treatment. […] Staying a healthy weight is one of the best things you can do for your overall health. It can lower your risk of many health problems, including heart disease, type-2 diabetes and some cancers. It may also be important for men with prostate cancer, as there is strong evidence that being overweight raises the risk of aggressive or advanced prostate cancer. […] Being a healthy weight may mean your prostate cancer is less likely to spread after surgery or radiotherapy. Hormone therapy might also be less effective if you’re very overweight. And staying a healthy weight may help you manage or reduce some of the side effects of treatments, such as urinary problems after surgery.

• #17 Diet and prostate cancer | Prostate Cancer UK

  https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/your-diet-and-physical-activity/

  Being active can also help with some of the side effects of treatment. For example, physical activity can help manage fatigue and sexual problems. It can also help maintain muscle strength and help you stay a healthy weight. Being a healthy weight may help to lower your risk of advanced prostate cancer. […] Hormone therapy may increase your risk of heart disease and type-2 diabetes. A healthy diet and being active can help prevent them. […] Regular physical activity can often help you deal with feelings of anxiety and depression and improve your day to day life.

• #18 What lifestyle changes can help me avoid prostate cancer? – Harvard Health

  https://www.health.harvard.edu/mens-health/what-lifestyle-changes-can-help-me-avoid-prostate-cancer

  Maintaining a healthy weight and avoiding obesity is linked to a lower chance of developing advanced prostate cancer. Also, limiting meat and added sugars may be good for prostate health. […] Some evidence suggests that regular exercise can lower a man’s likelihood of getting prostate cancer. In 2019, Harvard researchers published findings that showed men who engaged most frequently in vigorous activity had a 30% lower risk of developing advanced prostate cancer and a 25% lower risk of dying from prostate cancer compared with men who exercised the least. […] Men who ejaculate frequently appear to have a lower risk of prostate cancer. According to one long-running large study, men who ejaculated more than 21 times per month had a 20% lower prostate cancer risk than those who ejaculated four to seven times monthly.

• #19 Prostate cancer – Wikipedia

  https://en.wikipedia.org/wiki/Prostate_cancer

  No drug or vaccine is approved by regulatory agencies for the prevention of prostate cancer. Several studies have shown 5-reductase inhibitors both finasteride and dutasteride, which are used to treat non-cancerous enlarged prostate to reduce the total incidence of prostate cancer; however, it is unclear as of 2022 whether they reduce any cases of dangerous disease.

• #20 Prostate Cancer Prevention (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK65968/

  Chemoprevention with finasteride and dutasteride reduces the incidence of prostate cancer, but the evidence is inadequate to determine whether chemoprevention with finasteride or dutasteride reduces mortality from prostate cancer. […] In the Prostate Cancer Prevention Trial (PCPT), absolute reduction in incidence for more than 7 years with finasteride as compared with placebo was 6% (18.4% with finasteride and 24.4% with placebo); relative risk reduction (RRR) for incidence was 24.8% (95% confidence interval [CI], 18.6%30.6%). […] The Oncology Drugs Advisory Committee of the FDA examined both finasteride and dutasteride in 2010. Neither agent was recommended for use for chemoprevention of prostate cancer. […] The Selenium and Vitamin E Cancer Prevention Trial (SELECT [NCT00006392]) was a large randomized placebo-controlled trial of vitamin E and selenium. It showed no reduction in prostate cancer period prevalence, but an increased risk of prostate cancer with vitamin E alone.

• #21 Prostate cancer prevention: Ways to reduce your risk

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/in-depth/prostate-cancer-prevention/art-20045641

  There’s no proven prevention strategy for prostate cancer. But you may reduce your risk of prostate cancer by making healthy choices, such as exercising and eating a healthy diet. […] Researchers haven’t found a sure way to prevent prostate cancer. Study results often conflict with each other. And most studies aren’t designed to prove whether something can prevent prostate cancer. […] But healthcare professionals suggest that people with an average risk of prostate cancer make healthy lifestyle choices for prostate cancer prevention. Many of the things you can do for prostate cancer prevention are things that may help improve your health in general. […] For those with a very high risk of prostate cancer, there may be other ways to lower risk. These might include medicines. If you think you have a high risk of prostate cancer, talk with your health professional.

• #22 Prostate Cancer | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/prostate-cancer.html

  Prostate cancer is a type of cancer that starts in the prostate, a walnut-sized gland in the male reproductive system that helps produce semen and nourishes sperm. Prostate cancer forms when cells in the prostate become abnormal and start rapidly multiplying. […] Prostate cancer is the third most common cancer in the United States, with more than 191,000 new cases diagnosed each year. It is also one of the most treatable cancers, with a five-year survival rate of nearly 98%. […] Certain actions may help lower your risk of prostate cancer: Eat at least five servings of fruits and vegetables daily and eat less red meat. Decrease fat intake. Exercise regularly. Maintain your ideal weight. […] Other ways to prevent prostate cancer are being investigated. These include: Lycopenes: These substances found in tomatoes, pink grapefruit and watermelon may help prevent damage to cells. Proscar (finasteride) or Avodart (dutasteride): These medications can reduce the risk of low-grade prostate cancer. If you are at high risk for prostate cancer, talk to your urologist or another provider who is familiar with studies about these drugs.

• #23 How to Prevent Prostate Cancer? | Prostate Cancer Prevention | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/prevention.html

  There is no sure way to prevent prostate cancer. Many prostate cancer risk factors, such as age, race, and family history, cant be controlled. But there are some things you can do that might lower your risk of prostate cancer. […] Some studies have found that men with excess body weight have a higher risk of developing advanced prostate cancer or prostate cancer that is more likely to be fatal. […] Although not all studies agree, several have found a higher risk of prostate cancer in men whose diets are high in dairy products and calcium. […] For now, the best advice about diet and activity to possibly reduce the risk of prostate cancer is to: Get to and stay at a healthy weight. Be physically active. Follow a healthy eating pattern, which includes a variety of colorful fruits and vegetables and whole grains, and avoids or limits red and processed meats, sugar-sweetened beverages, and highly processed foods.

• #24 How to Prevent Prostate Cancer? | Prostate Cancer Prevention | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/prevention.html

  There is no sure way to prevent prostate cancer. Many prostate cancer risk factors, such as age, race, and family history, cant be controlled. But there are some things you can do that might lower your risk of prostate cancer. […] Some studies have found that men with excess body weight have a higher risk of developing advanced prostate cancer or prostate cancer that is more likely to be fatal. […] Although not all studies agree, several have found a higher risk of prostate cancer in men whose diets are high in dairy products and calcium. […] For now, the best advice about diet and activity to possibly reduce the risk of prostate cancer is to: Get to and stay at a healthy weight. Be physically active. Follow a healthy eating pattern, which includes a variety of colorful fruits and vegetables and whole grains, and avoids or limits red and processed meats, sugar-sweetened beverages, and highly processed foods.

• #25 How to Prevent Prostate Cancer? | Prostate Cancer Prevention | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/prevention.html

  There is no sure way to prevent prostate cancer. Many prostate cancer risk factors, such as age, race, and family history, cant be controlled. But there are some things you can do that might lower your risk of prostate cancer. […] Some studies have found that men with excess body weight have a higher risk of developing advanced prostate cancer or prostate cancer that is more likely to be fatal. […] Although not all studies agree, several have found a higher risk of prostate cancer in men whose diets are high in dairy products and calcium. […] For now, the best advice about diet and activity to possibly reduce the risk of prostate cancer is to: Get to and stay at a healthy weight. Be physically active. Follow a healthy eating pattern, which includes a variety of colorful fruits and vegetables and whole grains, and avoids or limits red and processed meats, sugar-sweetened beverages, and highly processed foods.

• #26 How to Prevent Prostate Cancer? | Prostate Cancer Prevention | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/prevention.html

  It may also be sensible to limit calcium supplements and to not get too much calcium in the diet. […] Some early studies suggested that taking vitamin E or selenium supplements might lower prostate cancer risk. […] But a large study known as the Selenium and Vitamin E Cancer Prevention Trial (SELECT) found that neither vitamin E nor selenium supplements lowered prostate cancer risk. […] Some drugs might help reduce the risk of prostate cancer. […] Large studies of both of these drugs have tested if they might also be useful in lowering prostate cancer risk. […] When the results were looked at more closely, the men who took these drugs had fewer low-grade prostate cancers, but they had about the same risk of higher-grade prostate cancers, which are more likely to grow and spread. […] Some research suggests that men who take a daily aspirin might have a lower risk of getting and dying from prostate cancer. […] Other drugs and dietary supplements that might help lower prostate cancer risk are now being studied. But so far, no drug or supplement has been found to be helpful in studies large enough for experts to recommend them.

• #27 Prostate Cancer | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/prostate-cancer.html

  Prostate cancer is a type of cancer that starts in the prostate, a walnut-sized gland in the male reproductive system that helps produce semen and nourishes sperm. Prostate cancer forms when cells in the prostate become abnormal and start rapidly multiplying. […] Prostate cancer is the third most common cancer in the United States, with more than 191,000 new cases diagnosed each year. It is also one of the most treatable cancers, with a five-year survival rate of nearly 98%. […] Certain actions may help lower your risk of prostate cancer: Eat at least five servings of fruits and vegetables daily and eat less red meat. Decrease fat intake. Exercise regularly. Maintain your ideal weight. […] Other ways to prevent prostate cancer are being investigated. These include: Lycopenes: These substances found in tomatoes, pink grapefruit and watermelon may help prevent damage to cells. Proscar (finasteride) or Avodart (dutasteride): These medications can reduce the risk of low-grade prostate cancer. If you are at high risk for prostate cancer, talk to your urologist or another provider who is familiar with studies about these drugs.

• #28 Diet and prostate cancer | Prostate Cancer UK

  https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/your-diet-and-physical-activity/

  A healthy diet is important for your overall health. It can help you stay a healthy weight and can lower your risk of health problems such as heart disease, type-2 diabetes and some cancers. A healthy diet can also help you recover if you’ve had prostate cancer surgery (radical prostatectomy). […] However, some changes to your diet may help reduce or manage some of the side effects of prostate cancer treatment. And some men with prostate cancer find that changing their diet helps them feel more in control. […] Physical activity is any type of body movement that uses energy. It doesn’t have to be a sport or going to the gym it could be walking, swimming or gardening. We don’t know for sure if physical activity can help slow the growth of prostate cancer, but we do know that it’s important for your overall health and wellbeing. It helps to prevent many health problems such as heart disease and type-2 diabetes, and can help you stay a healthy weight.

• #29 What lifestyle changes can help me avoid prostate cancer? – Harvard Health

  https://www.health.harvard.edu/mens-health/what-lifestyle-changes-can-help-me-avoid-prostate-cancer

  Maintaining a healthy weight and avoiding obesity is linked to a lower chance of developing advanced prostate cancer. Also, limiting meat and added sugars may be good for prostate health. […] Some evidence suggests that regular exercise can lower a man’s likelihood of getting prostate cancer. In 2019, Harvard researchers published findings that showed men who engaged most frequently in vigorous activity had a 30% lower risk of developing advanced prostate cancer and a 25% lower risk of dying from prostate cancer compared with men who exercised the least. […] Men who ejaculate frequently appear to have a lower risk of prostate cancer. According to one long-running large study, men who ejaculated more than 21 times per month had a 20% lower prostate cancer risk than those who ejaculated four to seven times monthly.

• #30 Diet and prostate cancer | Prostate Cancer UK

  https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/your-diet-and-physical-activity/

  Being active can also help with some of the side effects of treatment. For example, physical activity can help manage fatigue and sexual problems. It can also help maintain muscle strength and help you stay a healthy weight. Being a healthy weight may help to lower your risk of advanced prostate cancer. […] Hormone therapy may increase your risk of heart disease and type-2 diabetes. A healthy diet and being active can help prevent them. […] Regular physical activity can often help you deal with feelings of anxiety and depression and improve your day to day life.

• #31 Diet and prostate cancer | Prostate Cancer UK

  https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/your-diet-and-physical-activity/

  A healthy diet is important for general health and can help you stay a healthy weight. It can also help you manage the effects of prostate cancer and its treatment. […] Staying a healthy weight is one of the best things you can do for your overall health. It can lower your risk of many health problems, including heart disease, type-2 diabetes and some cancers. It may also be important for men with prostate cancer, as there is strong evidence that being overweight raises the risk of aggressive or advanced prostate cancer. […] Being a healthy weight may mean your prostate cancer is less likely to spread after surgery or radiotherapy. Hormone therapy might also be less effective if you’re very overweight. And staying a healthy weight may help you manage or reduce some of the side effects of treatments, such as urinary problems after surgery.

• #32 Diet and prostate cancer | Prostate Cancer UK

  https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/your-diet-and-physical-activity/

  A healthy diet is important for general health and can help you stay a healthy weight. It can also help you manage the effects of prostate cancer and its treatment. […] Staying a healthy weight is one of the best things you can do for your overall health. It can lower your risk of many health problems, including heart disease, type-2 diabetes and some cancers. It may also be important for men with prostate cancer, as there is strong evidence that being overweight raises the risk of aggressive or advanced prostate cancer. […] Being a healthy weight may mean your prostate cancer is less likely to spread after surgery or radiotherapy. Hormone therapy might also be less effective if you’re very overweight. And staying a healthy weight may help you manage or reduce some of the side effects of treatments, such as urinary problems after surgery.

• #33 Diet and prostate cancer | Prostate Cancer UK

  https://prostatecanceruk.org/prostate-information-and-support/living-with-prostate-cancer/your-diet-and-physical-activity/

  A healthy diet is important for general health and can help you stay a healthy weight. It can also help you manage the effects of prostate cancer and its treatment. […] Staying a healthy weight is one of the best things you can do for your overall health. It can lower your risk of many health problems, including heart disease, type-2 diabetes and some cancers. It may also be important for men with prostate cancer, as there is strong evidence that being overweight raises the risk of aggressive or advanced prostate cancer. […] Being a healthy weight may mean your prostate cancer is less likely to spread after surgery or radiotherapy. Hormone therapy might also be less effective if you’re very overweight. And staying a healthy weight may help you manage or reduce some of the side effects of treatments, such as urinary problems after surgery.

• #34 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The goal of screening for prostate cancer is to identify high-risk, localized prostate cancer that can be successfully treated, thereby preventing the morbidity and mortality associated with advanced or metastatic prostate cancer. […] Adequate evidence from randomized clinical trials (RCTs) shows that PSA-based screening programs in men aged 55 to 69 years may prevent approximately 1.3 deaths from prostate cancer over approximately 13 years per 1000 men screened. […] Screening programs may also prevent approximately 3 cases of metastatic prostate cancer per 1000 men screened. […] The USPSTF concludes with moderate certainty that the potential benefits of PSA-based screening for prostate cancer in men 70 years and older do not outweigh the expected harms. […] The USPSTF does not recommend screening for prostate cancer unless men express a preference for screening after being informed of and understanding the benefits and risks.

• #35 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The goal of screening for prostate cancer is to identify high-risk, localized prostate cancer that can be successfully treated, thereby preventing the morbidity and mortality associated with advanced or metastatic prostate cancer. […] Adequate evidence from randomized clinical trials (RCTs) shows that PSA-based screening programs in men aged 55 to 69 years may prevent approximately 1.3 deaths from prostate cancer over approximately 13 years per 1000 men screened. […] Screening programs may also prevent approximately 3 cases of metastatic prostate cancer per 1000 men screened. […] The USPSTF concludes with moderate certainty that the potential benefits of PSA-based screening for prostate cancer in men 70 years and older do not outweigh the expected harms. […] The USPSTF does not recommend screening for prostate cancer unless men express a preference for screening after being informed of and understanding the benefits and risks.

• #36 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The goal of screening for prostate cancer is to identify high-risk, localized prostate cancer that can be successfully treated, thereby preventing the morbidity and mortality associated with advanced or metastatic prostate cancer. […] Adequate evidence from randomized clinical trials (RCTs) shows that PSA-based screening programs in men aged 55 to 69 years may prevent approximately 1.3 deaths from prostate cancer over approximately 13 years per 1000 men screened. […] Screening programs may also prevent approximately 3 cases of metastatic prostate cancer per 1000 men screened. […] The USPSTF concludes with moderate certainty that the potential benefits of PSA-based screening for prostate cancer in men 70 years and older do not outweigh the expected harms. […] The USPSTF does not recommend screening for prostate cancer unless men express a preference for screening after being informed of and understanding the benefits and risks.

• #37 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The potential harms of screening, diagnostic procedures, and treatment occur soon after screening takes place. […] The USPSTF strongly encourages research on screening for and treatment of prostate cancer in African American men. […] Studies are needed to confirm that African American men who undergo screening receive similar or greater reductions in prostate cancer mortality compared with men in the general population, as well as to explore the optimal screening frequency and whether beginning screening before age 55 years provides additional benefits in African American men. […] The USPSTF does not recommend screening for prostate cancer in men, including African American men, older than 70 years. […] The USPSTF believes that a reasonable approach for clinicians is to inform men with a family history of prostate cancer, particularly those with multiple first-degree relatives with prostate cancer, about their increased risk of developing cancer as well as the potential earlier age at disease onset. […] The USPSTF does not recommend screening for prostate cancer in men, including men with a family history of prostate cancer, older than 70 years.

• #38 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The potential harms of screening, diagnostic procedures, and treatment occur soon after screening takes place. […] The USPSTF strongly encourages research on screening for and treatment of prostate cancer in African American men. […] Studies are needed to confirm that African American men who undergo screening receive similar or greater reductions in prostate cancer mortality compared with men in the general population, as well as to explore the optimal screening frequency and whether beginning screening before age 55 years provides additional benefits in African American men. […] The USPSTF does not recommend screening for prostate cancer in men, including African American men, older than 70 years. […] The USPSTF believes that a reasonable approach for clinicians is to inform men with a family history of prostate cancer, particularly those with multiple first-degree relatives with prostate cancer, about their increased risk of developing cancer as well as the potential earlier age at disease onset. […] The USPSTF does not recommend screening for prostate cancer in men, including men with a family history of prostate cancer, older than 70 years.

• #39 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  Approximately 1 in 10 men with advanced prostate cancer carries an inherited gene mutation. This can open a unique treatment toolbox to them, offer opportunities for leading-edge clinical trials and research, and may offer a potential lifesaving impact to their blood relatives. […] Nearly 12 percent of men with advanced prostate cancer carry inherited genes that increase their risk for faster-growing forms of the disease that are more likely to spread. Knowing whether you carry one of these genes may help your physician precisely tailor your prostate cancer treatment. […] You should consider genetic testing if you have metastatic prostate cancer. We also recommend genetic testing and counseling for men with prostate cancer who have: A family history of prostate cancer or several men in your family who have had it, One close family member who has had high-grade, advanced or metastatic prostate cancer, A family history of breast, ovarian or pancreatic cancer, A family member with a known genetic risk factor such as a mutation in BRCA1, BRCA2, ATM, CHEK2, etc.

• #40 Prostate Cancer Prevention (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK65968/

  Chemoprevention with finasteride and dutasteride reduces the incidence of prostate cancer, but the evidence is inadequate to determine whether chemoprevention with finasteride or dutasteride reduces mortality from prostate cancer. […] In the Prostate Cancer Prevention Trial (PCPT), absolute reduction in incidence for more than 7 years with finasteride as compared with placebo was 6% (18.4% with finasteride and 24.4% with placebo); relative risk reduction (RRR) for incidence was 24.8% (95% confidence interval [CI], 18.6%30.6%). […] The Oncology Drugs Advisory Committee of the FDA examined both finasteride and dutasteride in 2010. Neither agent was recommended for use for chemoprevention of prostate cancer. […] The Selenium and Vitamin E Cancer Prevention Trial (SELECT [NCT00006392]) was a large randomized placebo-controlled trial of vitamin E and selenium. It showed no reduction in prostate cancer period prevalence, but an increased risk of prostate cancer with vitamin E alone.

• #41 Prostate Cancer | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/prostate-cancer.html

  Prostate cancer is a type of cancer that starts in the prostate, a walnut-sized gland in the male reproductive system that helps produce semen and nourishes sperm. Prostate cancer forms when cells in the prostate become abnormal and start rapidly multiplying. […] Prostate cancer is the third most common cancer in the United States, with more than 191,000 new cases diagnosed each year. It is also one of the most treatable cancers, with a five-year survival rate of nearly 98%. […] Certain actions may help lower your risk of prostate cancer: Eat at least five servings of fruits and vegetables daily and eat less red meat. Decrease fat intake. Exercise regularly. Maintain your ideal weight. […] Other ways to prevent prostate cancer are being investigated. These include: Lycopenes: These substances found in tomatoes, pink grapefruit and watermelon may help prevent damage to cells. Proscar (finasteride) or Avodart (dutasteride): These medications can reduce the risk of low-grade prostate cancer. If you are at high risk for prostate cancer, talk to your urologist or another provider who is familiar with studies about these drugs.

• #42 Prostate Cancer Prevention (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK65968/

  Chemoprevention with finasteride and dutasteride reduces the incidence of prostate cancer, but the evidence is inadequate to determine whether chemoprevention with finasteride or dutasteride reduces mortality from prostate cancer. […] In the Prostate Cancer Prevention Trial (PCPT), absolute reduction in incidence for more than 7 years with finasteride as compared with placebo was 6% (18.4% with finasteride and 24.4% with placebo); relative risk reduction (RRR) for incidence was 24.8% (95% confidence interval [CI], 18.6%30.6%). […] The Oncology Drugs Advisory Committee of the FDA examined both finasteride and dutasteride in 2010. Neither agent was recommended for use for chemoprevention of prostate cancer. […] The Selenium and Vitamin E Cancer Prevention Trial (SELECT [NCT00006392]) was a large randomized placebo-controlled trial of vitamin E and selenium. It showed no reduction in prostate cancer period prevalence, but an increased risk of prostate cancer with vitamin E alone.

• #43 Prostate Cancer Prevention (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK65968/

  Chemoprevention with finasteride and dutasteride reduces the incidence of prostate cancer, but the evidence is inadequate to determine whether chemoprevention with finasteride or dutasteride reduces mortality from prostate cancer. […] In the Prostate Cancer Prevention Trial (PCPT), absolute reduction in incidence for more than 7 years with finasteride as compared with placebo was 6% (18.4% with finasteride and 24.4% with placebo); relative risk reduction (RRR) for incidence was 24.8% (95% confidence interval [CI], 18.6%30.6%). […] The Oncology Drugs Advisory Committee of the FDA examined both finasteride and dutasteride in 2010. Neither agent was recommended for use for chemoprevention of prostate cancer. […] The Selenium and Vitamin E Cancer Prevention Trial (SELECT [NCT00006392]) was a large randomized placebo-controlled trial of vitamin E and selenium. It showed no reduction in prostate cancer period prevalence, but an increased risk of prostate cancer with vitamin E alone.

• #44 Prostate Cancer | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/prostate-cancer.html

  Prostate cancer is a type of cancer that starts in the prostate, a walnut-sized gland in the male reproductive system that helps produce semen and nourishes sperm. Prostate cancer forms when cells in the prostate become abnormal and start rapidly multiplying. […] Prostate cancer is the third most common cancer in the United States, with more than 191,000 new cases diagnosed each year. It is also one of the most treatable cancers, with a five-year survival rate of nearly 98%. […] Certain actions may help lower your risk of prostate cancer: Eat at least five servings of fruits and vegetables daily and eat less red meat. Decrease fat intake. Exercise regularly. Maintain your ideal weight. […] Other ways to prevent prostate cancer are being investigated. These include: Lycopenes: These substances found in tomatoes, pink grapefruit and watermelon may help prevent damage to cells. Proscar (finasteride) or Avodart (dutasteride): These medications can reduce the risk of low-grade prostate cancer. If you are at high risk for prostate cancer, talk to your urologist or another provider who is familiar with studies about these drugs.

• #45 Prostate Cancer Prevention (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK65968/

  Chemoprevention with finasteride and dutasteride reduces the incidence of prostate cancer, but the evidence is inadequate to determine whether chemoprevention with finasteride or dutasteride reduces mortality from prostate cancer. […] In the Prostate Cancer Prevention Trial (PCPT), absolute reduction in incidence for more than 7 years with finasteride as compared with placebo was 6% (18.4% with finasteride and 24.4% with placebo); relative risk reduction (RRR) for incidence was 24.8% (95% confidence interval [CI], 18.6%30.6%). […] The Oncology Drugs Advisory Committee of the FDA examined both finasteride and dutasteride in 2010. Neither agent was recommended for use for chemoprevention of prostate cancer. […] The Selenium and Vitamin E Cancer Prevention Trial (SELECT [NCT00006392]) was a large randomized placebo-controlled trial of vitamin E and selenium. It showed no reduction in prostate cancer period prevalence, but an increased risk of prostate cancer with vitamin E alone.

• #46 Prostate Cancer Prevention (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK65968/

  Compared with the placebo group in which 529 men developed prostate cancer, there was a statistically significant increase in prostate cancer in the vitamin E group (620 cases) but not in the selenium plus vitamin E group (555 cases) or in the selenium group (575 cases). The magnitude of increase in prostate cancer risk with vitamin E alone was 17%.

• #47 How to Prevent Prostate Cancer? | Prostate Cancer Prevention | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/prevention.html

  It may also be sensible to limit calcium supplements and to not get too much calcium in the diet. […] Some early studies suggested that taking vitamin E or selenium supplements might lower prostate cancer risk. […] But a large study known as the Selenium and Vitamin E Cancer Prevention Trial (SELECT) found that neither vitamin E nor selenium supplements lowered prostate cancer risk. […] Some drugs might help reduce the risk of prostate cancer. […] Large studies of both of these drugs have tested if they might also be useful in lowering prostate cancer risk. […] When the results were looked at more closely, the men who took these drugs had fewer low-grade prostate cancers, but they had about the same risk of higher-grade prostate cancers, which are more likely to grow and spread. […] Some research suggests that men who take a daily aspirin might have a lower risk of getting and dying from prostate cancer. […] Other drugs and dietary supplements that might help lower prostate cancer risk are now being studied. But so far, no drug or supplement has been found to be helpful in studies large enough for experts to recommend them.

• #48 How to Prevent Prostate Cancer? | Prostate Cancer Prevention | American Cancer Society

  https://www.cancer.org/cancer/types/prostate-cancer/causes-risks-prevention/prevention.html

  It may also be sensible to limit calcium supplements and to not get too much calcium in the diet. […] Some early studies suggested that taking vitamin E or selenium supplements might lower prostate cancer risk. […] But a large study known as the Selenium and Vitamin E Cancer Prevention Trial (SELECT) found that neither vitamin E nor selenium supplements lowered prostate cancer risk. […] Some drugs might help reduce the risk of prostate cancer. […] Large studies of both of these drugs have tested if they might also be useful in lowering prostate cancer risk. […] When the results were looked at more closely, the men who took these drugs had fewer low-grade prostate cancers, but they had about the same risk of higher-grade prostate cancers, which are more likely to grow and spread. […] Some research suggests that men who take a daily aspirin might have a lower risk of getting and dying from prostate cancer. […] Other drugs and dietary supplements that might help lower prostate cancer risk are now being studied. But so far, no drug or supplement has been found to be helpful in studies large enough for experts to recommend them.

• #49 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  Approximately 1 in 10 men with advanced prostate cancer carries an inherited gene mutation. This can open a unique treatment toolbox to them, offer opportunities for leading-edge clinical trials and research, and may offer a potential lifesaving impact to their blood relatives. […] Nearly 12 percent of men with advanced prostate cancer carry inherited genes that increase their risk for faster-growing forms of the disease that are more likely to spread. Knowing whether you carry one of these genes may help your physician precisely tailor your prostate cancer treatment. […] You should consider genetic testing if you have metastatic prostate cancer. We also recommend genetic testing and counseling for men with prostate cancer who have: A family history of prostate cancer or several men in your family who have had it, One close family member who has had high-grade, advanced or metastatic prostate cancer, A family history of breast, ovarian or pancreatic cancer, A family member with a known genetic risk factor such as a mutation in BRCA1, BRCA2, ATM, CHEK2, etc.

• #50 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  Approximately 1 in 10 men with advanced prostate cancer carries an inherited gene mutation. This can open a unique treatment toolbox to them, offer opportunities for leading-edge clinical trials and research, and may offer a potential lifesaving impact to their blood relatives. […] Nearly 12 percent of men with advanced prostate cancer carry inherited genes that increase their risk for faster-growing forms of the disease that are more likely to spread. Knowing whether you carry one of these genes may help your physician precisely tailor your prostate cancer treatment. […] You should consider genetic testing if you have metastatic prostate cancer. We also recommend genetic testing and counseling for men with prostate cancer who have: A family history of prostate cancer or several men in your family who have had it, One close family member who has had high-grade, advanced or metastatic prostate cancer, A family history of breast, ovarian or pancreatic cancer, A family member with a known genetic risk factor such as a mutation in BRCA1, BRCA2, ATM, CHEK2, etc.

• #51 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  Approximately 1 in 10 men with advanced prostate cancer carries an inherited gene mutation. This can open a unique treatment toolbox to them, offer opportunities for leading-edge clinical trials and research, and may offer a potential lifesaving impact to their blood relatives. […] Nearly 12 percent of men with advanced prostate cancer carry inherited genes that increase their risk for faster-growing forms of the disease that are more likely to spread. Knowing whether you carry one of these genes may help your physician precisely tailor your prostate cancer treatment. […] You should consider genetic testing if you have metastatic prostate cancer. We also recommend genetic testing and counseling for men with prostate cancer who have: A family history of prostate cancer or several men in your family who have had it, One close family member who has had high-grade, advanced or metastatic prostate cancer, A family history of breast, ovarian or pancreatic cancer, A family member with a known genetic risk factor such as a mutation in BRCA1, BRCA2, ATM, CHEK2, etc.

• #52 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  Approximately 1 in 10 men with advanced prostate cancer carries an inherited gene mutation. This can open a unique treatment toolbox to them, offer opportunities for leading-edge clinical trials and research, and may offer a potential lifesaving impact to their blood relatives. […] Nearly 12 percent of men with advanced prostate cancer carry inherited genes that increase their risk for faster-growing forms of the disease that are more likely to spread. Knowing whether you carry one of these genes may help your physician precisely tailor your prostate cancer treatment. […] You should consider genetic testing if you have metastatic prostate cancer. We also recommend genetic testing and counseling for men with prostate cancer who have: A family history of prostate cancer or several men in your family who have had it, One close family member who has had high-grade, advanced or metastatic prostate cancer, A family history of breast, ovarian or pancreatic cancer, A family member with a known genetic risk factor such as a mutation in BRCA1, BRCA2, ATM, CHEK2, etc.

• #53 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  Approximately 1 in 10 men with advanced prostate cancer carries an inherited gene mutation. This can open a unique treatment toolbox to them, offer opportunities for leading-edge clinical trials and research, and may offer a potential lifesaving impact to their blood relatives. […] Nearly 12 percent of men with advanced prostate cancer carry inherited genes that increase their risk for faster-growing forms of the disease that are more likely to spread. Knowing whether you carry one of these genes may help your physician precisely tailor your prostate cancer treatment. […] You should consider genetic testing if you have metastatic prostate cancer. We also recommend genetic testing and counseling for men with prostate cancer who have: A family history of prostate cancer or several men in your family who have had it, One close family member who has had high-grade, advanced or metastatic prostate cancer, A family history of breast, ovarian or pancreatic cancer, A family member with a known genetic risk factor such as a mutation in BRCA1, BRCA2, ATM, CHEK2, etc.

• #54 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  Approximately 1 in 10 men with advanced prostate cancer carries an inherited gene mutation. This can open a unique treatment toolbox to them, offer opportunities for leading-edge clinical trials and research, and may offer a potential lifesaving impact to their blood relatives. […] Nearly 12 percent of men with advanced prostate cancer carry inherited genes that increase their risk for faster-growing forms of the disease that are more likely to spread. Knowing whether you carry one of these genes may help your physician precisely tailor your prostate cancer treatment. […] You should consider genetic testing if you have metastatic prostate cancer. We also recommend genetic testing and counseling for men with prostate cancer who have: A family history of prostate cancer or several men in your family who have had it, One close family member who has had high-grade, advanced or metastatic prostate cancer, A family history of breast, ovarian or pancreatic cancer, A family member with a known genetic risk factor such as a mutation in BRCA1, BRCA2, ATM, CHEK2, etc.

• #55 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  Approximately 1 in 10 men with advanced prostate cancer carries an inherited gene mutation. This can open a unique treatment toolbox to them, offer opportunities for leading-edge clinical trials and research, and may offer a potential lifesaving impact to their blood relatives. […] Nearly 12 percent of men with advanced prostate cancer carry inherited genes that increase their risk for faster-growing forms of the disease that are more likely to spread. Knowing whether you carry one of these genes may help your physician precisely tailor your prostate cancer treatment. […] You should consider genetic testing if you have metastatic prostate cancer. We also recommend genetic testing and counseling for men with prostate cancer who have: A family history of prostate cancer or several men in your family who have had it, One close family member who has had high-grade, advanced or metastatic prostate cancer, A family history of breast, ovarian or pancreatic cancer, A family member with a known genetic risk factor such as a mutation in BRCA1, BRCA2, ATM, CHEK2, etc.

• #56 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  If testing shows you have a gene mutation that is linked to inherited cancer risk, your blood relatives might be at higher risk, too. The Prostate Cancer Genetics Clinic at Fred Hutch can help refer your family members for genetic counseling and testing, if appropriate. We can also guide them to resources for screening and early cancer prevention. […] Research led by scientists from Fred Hutch and the University of Washington are discovering new answers. If you have prostate cancer or metastatic prostate cancer, you can receive innovative new therapies that can help you while providing valuable information that can help physicians better prevent, diagnose and treat others who develop prostate cancer. […] Patients with any stage of prostate cancer can find out if they have an inherited gene mutation by participating in The Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness (PROMISE) Study. This is important information to have since people with prostate cancer who have these mutations may have more precise treatment options and more clinical trial options.

• #57 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  If testing shows you have a gene mutation that is linked to inherited cancer risk, your blood relatives might be at higher risk, too. The Prostate Cancer Genetics Clinic at Fred Hutch can help refer your family members for genetic counseling and testing, if appropriate. We can also guide them to resources for screening and early cancer prevention. […] Research led by scientists from Fred Hutch and the University of Washington are discovering new answers. If you have prostate cancer or metastatic prostate cancer, you can receive innovative new therapies that can help you while providing valuable information that can help physicians better prevent, diagnose and treat others who develop prostate cancer. […] Patients with any stage of prostate cancer can find out if they have an inherited gene mutation by participating in The Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness (PROMISE) Study. This is important information to have since people with prostate cancer who have these mutations may have more precise treatment options and more clinical trial options.

• #58 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  If testing shows you have a gene mutation that is linked to inherited cancer risk, your blood relatives might be at higher risk, too. The Prostate Cancer Genetics Clinic at Fred Hutch can help refer your family members for genetic counseling and testing, if appropriate. We can also guide them to resources for screening and early cancer prevention. […] Research led by scientists from Fred Hutch and the University of Washington are discovering new answers. If you have prostate cancer or metastatic prostate cancer, you can receive innovative new therapies that can help you while providing valuable information that can help physicians better prevent, diagnose and treat others who develop prostate cancer. […] Patients with any stage of prostate cancer can find out if they have an inherited gene mutation by participating in The Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness (PROMISE) Study. This is important information to have since people with prostate cancer who have these mutations may have more precise treatment options and more clinical trial options.

• #59 Prostate Cancer | Huntsman Cancer Institute | University of Utah Health

  https://healthcare.utah.edu/huntsmancancerinstitute/urologic-cancer/prostate-cancer

  We also have a portfolio of therapeutic options outside of standard care, and our clinical care delivery is unparalleled. Our multidisciplinary tumor boards consult on every patient case, looking at imaging, making sure all therapeutic portfolios are considered, and leaving no stone unturned for treatment. […] Additionally, we offer a Prostate Cancer Risk Clinic for men at increased risk due to genetic factors or family history, providing personalized screening and prevention strategies. […] We continue to be at the forefront of prostate cancer research, focusing on developing novel treatments and improving patient outcomes. […] A notable achievement is our TALAPRO-2 trial, which demonstrated that a combination of enzalutamide and talazoparib significantly improves overall survival rates in patients with metastatic prostate cancer compared to standard therapy. […] Learn more about ways to prevent cancer and about cancer screenings.

• #60 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  A genetic counselor can also determine if genetic testing could be helpful for you, based on your personal and family medical and health history. After you have had genetic testing, a genetic counselor can offer information about cancer screening options and steps you can take to help prevent cancer, based on your results.

• #61 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  If testing shows you have a gene mutation that is linked to inherited cancer risk, your blood relatives might be at higher risk, too. The Prostate Cancer Genetics Clinic at Fred Hutch can help refer your family members for genetic counseling and testing, if appropriate. We can also guide them to resources for screening and early cancer prevention. […] Research led by scientists from Fred Hutch and the University of Washington are discovering new answers. If you have prostate cancer or metastatic prostate cancer, you can receive innovative new therapies that can help you while providing valuable information that can help physicians better prevent, diagnose and treat others who develop prostate cancer. […] Patients with any stage of prostate cancer can find out if they have an inherited gene mutation by participating in The Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness (PROMISE) Study. This is important information to have since people with prostate cancer who have these mutations may have more precise treatment options and more clinical trial options.

• #62 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The potential harms of screening, diagnostic procedures, and treatment occur soon after screening takes place. […] The USPSTF strongly encourages research on screening for and treatment of prostate cancer in African American men. […] Studies are needed to confirm that African American men who undergo screening receive similar or greater reductions in prostate cancer mortality compared with men in the general population, as well as to explore the optimal screening frequency and whether beginning screening before age 55 years provides additional benefits in African American men. […] The USPSTF does not recommend screening for prostate cancer in men, including African American men, older than 70 years. […] The USPSTF believes that a reasonable approach for clinicians is to inform men with a family history of prostate cancer, particularly those with multiple first-degree relatives with prostate cancer, about their increased risk of developing cancer as well as the potential earlier age at disease onset. […] The USPSTF does not recommend screening for prostate cancer in men, including men with a family history of prostate cancer, older than 70 years.

• #63 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  A genetic counselor can also determine if genetic testing could be helpful for you, based on your personal and family medical and health history. After you have had genetic testing, a genetic counselor can offer information about cancer screening options and steps you can take to help prevent cancer, based on your results.

• #64 Treatment for Metastatic Prostate Cancer Often Suboptimal – NCI

  https://www.cancer.gov/news-events/cancer-currents-blog/2025/metastatic-prostate-cancer-combination-treatments

  Medical guidelines with the recommended treatments for metastatic prostate cancer are often not being followed in everyday care by doctors, a new study indicates. […] Guidelines in the United States now recommend giving a combination of two different drugs to block hormones in two different ways. […] In the United States, the majority of patients aren’t receiving life-prolonging combination therapies, despite the fact that clinical trials have shown that they lead to a really meaningful improvement in overall survival, Dr. Agarwal said. […] One drug alone is no longer sufficient for these patients, said Dr. Agarwal. Combining two [or more] really improves survival without compromising quality of life. […] Multiple clinical trials have shown that people who receive combination therapy when their disease is still hormone sensitive live longer than those who get it later, after their disease becomes hormone resistant. […] So the message here is: Don’t wait for disease progression, he said.

• #65 Treatment for Metastatic Prostate Cancer Often Suboptimal – NCI

  https://www.cancer.gov/news-events/cancer-currents-blog/2025/metastatic-prostate-cancer-combination-treatments

  Medical guidelines with the recommended treatments for metastatic prostate cancer are often not being followed in everyday care by doctors, a new study indicates. […] Guidelines in the United States now recommend giving a combination of two different drugs to block hormones in two different ways. […] In the United States, the majority of patients aren’t receiving life-prolonging combination therapies, despite the fact that clinical trials have shown that they lead to a really meaningful improvement in overall survival, Dr. Agarwal said. […] One drug alone is no longer sufficient for these patients, said Dr. Agarwal. Combining two [or more] really improves survival without compromising quality of life. […] Multiple clinical trials have shown that people who receive combination therapy when their disease is still hormone sensitive live longer than those who get it later, after their disease becomes hormone resistant. […] So the message here is: Don’t wait for disease progression, he said.

• #66 Treatment for Metastatic Prostate Cancer Often Suboptimal – NCI

  https://www.cancer.gov/news-events/cancer-currents-blog/2025/metastatic-prostate-cancer-combination-treatments

  Medical guidelines with the recommended treatments for metastatic prostate cancer are often not being followed in everyday care by doctors, a new study indicates. […] Guidelines in the United States now recommend giving a combination of two different drugs to block hormones in two different ways. […] In the United States, the majority of patients aren’t receiving life-prolonging combination therapies, despite the fact that clinical trials have shown that they lead to a really meaningful improvement in overall survival, Dr. Agarwal said. […] One drug alone is no longer sufficient for these patients, said Dr. Agarwal. Combining two [or more] really improves survival without compromising quality of life. […] Multiple clinical trials have shown that people who receive combination therapy when their disease is still hormone sensitive live longer than those who get it later, after their disease becomes hormone resistant. […] So the message here is: Don’t wait for disease progression, he said.

• #67 Treatment for Metastatic Prostate Cancer Often Suboptimal – NCI

  https://www.cancer.gov/news-events/cancer-currents-blog/2025/metastatic-prostate-cancer-combination-treatments

  Medical guidelines with the recommended treatments for metastatic prostate cancer are often not being followed in everyday care by doctors, a new study indicates. […] Guidelines in the United States now recommend giving a combination of two different drugs to block hormones in two different ways. […] In the United States, the majority of patients aren’t receiving life-prolonging combination therapies, despite the fact that clinical trials have shown that they lead to a really meaningful improvement in overall survival, Dr. Agarwal said. […] One drug alone is no longer sufficient for these patients, said Dr. Agarwal. Combining two [or more] really improves survival without compromising quality of life. […] Multiple clinical trials have shown that people who receive combination therapy when their disease is still hormone sensitive live longer than those who get it later, after their disease becomes hormone resistant. […] So the message here is: Don’t wait for disease progression, he said.

• #68 Treatment for Metastatic Prostate Cancer Often Suboptimal – NCI

  https://www.cancer.gov/news-events/cancer-currents-blog/2025/metastatic-prostate-cancer-combination-treatments

  Medical guidelines with the recommended treatments for metastatic prostate cancer are often not being followed in everyday care by doctors, a new study indicates. […] Guidelines in the United States now recommend giving a combination of two different drugs to block hormones in two different ways. […] In the United States, the majority of patients aren’t receiving life-prolonging combination therapies, despite the fact that clinical trials have shown that they lead to a really meaningful improvement in overall survival, Dr. Agarwal said. […] One drug alone is no longer sufficient for these patients, said Dr. Agarwal. Combining two [or more] really improves survival without compromising quality of life. […] Multiple clinical trials have shown that people who receive combination therapy when their disease is still hormone sensitive live longer than those who get it later, after their disease becomes hormone resistant. […] So the message here is: Don’t wait for disease progression, he said.

• #69 Cytoreductive treatment strategies for de novo metastatic prostate cancer | Nature Reviews Clinical Oncology

  https://www.nature.com/articles/s41571-019-0284-3

  The treatment of de novo, synchronous castration-sensitive metastatic prostate cancer has undergone a revolution with the advent of novel hormone therapies and life-prolonging chemotherapy for use in combination with androgen-deprivation therapy. […] Men with low-burden metastatic (oligometastatic) prostate cancer can have localized disease control and substantial delays in disease progression with local cytoreductive treatment of the primary tumour (with radiotherapy, surgery or minimally invasive ablative therapies) in combination with metastasis-directed therapies (typically with stereotactic ablative radiotherapy). […] Local cytoreduction of a primary prostate cancer (and/or metastases thereof) has various effects on tumour-derived factors that are likely to translate into survival benefits for patients.

• #70 Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection | Actas Urológicas Españolas (English Edition)

  https://www.elsevier.es/es-revista-actas-urologicas-espanolas-english-392-avance-resumen-recommendations-on-treatment-metastatic-hormone-sensitive-S2173578624000684

  In metastatic disease, local treatment of the primary tumor has a biological rationale, by decreasing the total tumor burden and inducing an immunogenic response that releases substances that trigger systemic anti-tumor effects (abscopal effects). […] Prostate radiotherapy should be recommended in patients with mHSPC and low tumor volume. Treatment in other subgroups should be individualized and justified by the benefits observed in the reduction of local events. […] Clinically, metastasis-directed therapy (MDT), commonly by stereotactic body radiotherapy (SBRT) has been shown to improve PFS. […] Pending the results of randomized trials, treatment with MDT (and more specifically SBRT) in oligometastatic disease seems to be an individualized option in well-informed patients and within the framework of multidisciplinary committees. […] The therapeutic landscape of mHSPC has rapidly evolved, outpacing treatment with ADT monotherapy and ADT plus docetaxel.

• #71 Diagnosed with advanced (metastatic) prostate cancer? – Prostate Matters

  https://prostatematters.co.nz/prostate-cancer/diagnosed-with-advanced-metastatic-prostate-cancer/

  The information on this page is relevant if you have had a recently been diagnosed with metastatic prostate cancer, that is prostate cancer that has spread well beyond the prostate gland itself, into other areas of the body. This is called advanced or in medical terms metastatic prostate cancer. […] Hormone therapy works by preventing your body producing testosterone and by stopping testosterone reaching cancer cells. Prostate cancer uses testosterone to grow. Hormone therapy once commenced in metastatic prostate cancer is normally lifelong. This will help control the spread of prostate cancer and prevent symptoms (such as bone pain) but does not provide a cure. […] Despite the medical treatments available, the main cancer in the prostate is not normally treated as it was unclear the benefit from doing so. However, there is new evidence that some men who had a few or limited number of deposits (oligometastatic prostate cancer) may benefit from treating the main cancer inside the prostate in addition to the previously mentioned medical treatments. […] There is some new evidence that cancer deposits can communicate with each other independently. Therefore, some clinicians are exploring whether there is any benefit in treating specific areas of cancer outside of the prostate in addition to medical therapy.

• #72 Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection | Actas Urológicas Españolas (English Edition)

  https://www.elsevier.es/es-revista-actas-urologicas-espanolas-english-392-avance-resumen-recommendations-on-treatment-metastatic-hormone-sensitive-S2173578624000684

  In metastatic disease, local treatment of the primary tumor has a biological rationale, by decreasing the total tumor burden and inducing an immunogenic response that releases substances that trigger systemic anti-tumor effects (abscopal effects). […] Prostate radiotherapy should be recommended in patients with mHSPC and low tumor volume. Treatment in other subgroups should be individualized and justified by the benefits observed in the reduction of local events. […] Clinically, metastasis-directed therapy (MDT), commonly by stereotactic body radiotherapy (SBRT) has been shown to improve PFS. […] Pending the results of randomized trials, treatment with MDT (and more specifically SBRT) in oligometastatic disease seems to be an individualized option in well-informed patients and within the framework of multidisciplinary committees. […] The therapeutic landscape of mHSPC has rapidly evolved, outpacing treatment with ADT monotherapy and ADT plus docetaxel.

• #73 Attacking metastatic prostate cancer early with combination treatment approach improves outcomes in preliminary study | UCLA Health

  https://www.uclahealth.org/news/release/attacking-metastatic-prostate-cancer-early-with-combination

  A team of UCLA Health Jonsson Comprehensive Cancer Center investigators has shown the combination of a short course of powerful and intense hormonal therapy with targeted radiation is safe and effective in treating people with prostate cancer that has come back and has spread to other parts of the body. […] These results suggest a substantial improvement and strongly suggest there can be a meaningful impact namely, delaying the need for hormonal therapy and thus without the significant side effects of it by attacking metastatic prostate cancer early. […] One way to prolong the use of hormonal therapy while controlling PSA levels is to leverage a combination of therapies, including stereotactic body radiation therapy (SBRT), which delivers highly focused and intense doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues in short duration. […] The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen.

• #74 Attacking metastatic prostate cancer early with combination treatment approach improves outcomes in preliminary study | UCLA Health

  https://www.uclahealth.org/news/release/attacking-metastatic-prostate-cancer-early-with-combination

  A team of UCLA Health Jonsson Comprehensive Cancer Center investigators has shown the combination of a short course of powerful and intense hormonal therapy with targeted radiation is safe and effective in treating people with prostate cancer that has come back and has spread to other parts of the body. […] These results suggest a substantial improvement and strongly suggest there can be a meaningful impact namely, delaying the need for hormonal therapy and thus without the significant side effects of it by attacking metastatic prostate cancer early. […] One way to prolong the use of hormonal therapy while controlling PSA levels is to leverage a combination of therapies, including stereotactic body radiation therapy (SBRT), which delivers highly focused and intense doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues in short duration. […] The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen.

• #75 Pluvicto for Metastatic Prostate Cancer | The University of Kansas Cancer Center

  https://www.kucancercenter.org/cancer/cancer-treatments/pluvicto

  The University of Kansas Cancer Center is the first and only cancer center in the region to offer an innovative prostate cancer treatment for men with metastatic prostate cancer. […] Pluvicto is a new targeted therapy for metastatic prostate cancer. […] While Pluvicto is not a cure for metastatic prostate cancer, it can give you a longer life and improved quality of life with reduced side effects. […] Pluvicto is a new targeted therapy for metastatic prostate cancer that delivers radiation treatment directly to prostate-specific membrane antigen or PSMA-positive cancer cells. […] To receive Pluvicto, you must have metastatic prostate cancer that is hormone-resistant and tumors that overproduce the PSMA protein. […] Pluvicto is not a cure for metastatic prostate cancer, but it can give you a longer life and improved quality of life with reduced side effects.

• #76 Pluvicto for Metastatic Prostate Cancer | The University of Kansas Cancer Center

  https://www.kucancercenter.org/cancer/cancer-treatments/pluvicto

  The University of Kansas Cancer Center is the first and only cancer center in the region to offer an innovative prostate cancer treatment for men with metastatic prostate cancer. […] Pluvicto is a new targeted therapy for metastatic prostate cancer. […] While Pluvicto is not a cure for metastatic prostate cancer, it can give you a longer life and improved quality of life with reduced side effects. […] Pluvicto is a new targeted therapy for metastatic prostate cancer that delivers radiation treatment directly to prostate-specific membrane antigen or PSMA-positive cancer cells. […] To receive Pluvicto, you must have metastatic prostate cancer that is hormone-resistant and tumors that overproduce the PSMA protein. […] Pluvicto is not a cure for metastatic prostate cancer, but it can give you a longer life and improved quality of life with reduced side effects.

• #77 Game-changing prostate cancer treatment available at UT Health San Antonio – UT Health San Antonio

  https://news.uthscsa.edu/game-changing-prostate-cancer-treatment-available-at-ut-health-san-antonio/

  Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is the only institution in South Texas offering a novel targeted molecular therapy using a radioactive drug to fight metastatic castration-resistant prostate cancer. It’s called Lutetium-177 PSMA therapy for prostate cancer (Pluvicto). […] Vroman said the hope for the future is that the treatment will be approved for use on patients long before the disease progresses to other parts of the body. […] “The incidence of this cancer is just going to continue to increase. So, our overall goal is if we can get this treatment to these patients even earlier in their disease process, it will prolong survival and save a lot of overall costs associated with prostate cancer care,” she said.

• #78 An Emerging Treatment for Metastatic Prostate Cancer | Cancer Today

  https://www.cancertodaymag.org/cancer-talk/an-emerging-treatment-for-metastatic-prostate-cancer/

  A drug that delivers radioactive particles to prostate cancer cells increases overall survival for metastatic castration-resistant prostate cancer. […] Improvements in treatments for advanced prostate cancer have greatly prolonged survival and quality of life. However, when patients stop responding to the new treatments, there is an unmet medical need for additional therapy, says Howard Soule, the executive vice president and chief science officer at the Prostate Cancer Foundation, a nonprofit organization that funds PSMA research. […] He adds that PSMA therapy may also have applications in early-stage prostate cancer, and may be used in combination with other drugs, such as PARP inhibitors or immunotherapy, to deliver therapeutics to the cancer cells. […] Novartis, which manufactures 177Lu-PSMA-617, plans to submit it for FDA approval later this year. In addition, ongoing and planned trials will look at the drugs potential uses in other settings, such as with earlier-stage prostate cancer.

• #79 Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection | Actas Urológicas Españolas (English Edition)

  https://www.elsevier.es/es-revista-actas-urologicas-espanolas-english-392-avance-resumen-recommendations-on-treatment-metastatic-hormone-sensitive-S2173578624000684

  Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection […] The standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is now a combination of androgen deprivation therapy plus an androgen receptor-targeted therapy (abiraterone, apalutamide, enzalutamide or darolutamide), with or without chemotherapy (docetaxel). […] Treatment for metastatic hormone-sensitive prostate cancer (mHSPC) consists of androgen deprivation therapy (ADT) plus an androgen receptor-targeted therapy (abiraterone, apalutamide, enzalutamide or darolutamide), with or without the addition of docetaxel and/or locoregional radiotherapy in selected patients. […] According to different subgroup analyses in large, randomized trials and retrospective analyses, local treatment of the primary tumor in the face of metastatic disease would have an impact on survival, mainly in those patients classified as oligometastatic.

• #80 Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection | Actas Urológicas Españolas (English Edition)

  https://www.elsevier.es/es-revista-actas-urologicas-espanolas-english-392-avance-resumen-recommendations-on-treatment-metastatic-hormone-sensitive-S2173578624000684

  Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection […] The standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC) is now a combination of androgen deprivation therapy plus an androgen receptor-targeted therapy (abiraterone, apalutamide, enzalutamide or darolutamide), with or without chemotherapy (docetaxel). […] Treatment for metastatic hormone-sensitive prostate cancer (mHSPC) consists of androgen deprivation therapy (ADT) plus an androgen receptor-targeted therapy (abiraterone, apalutamide, enzalutamide or darolutamide), with or without the addition of docetaxel and/or locoregional radiotherapy in selected patients. […] According to different subgroup analyses in large, randomized trials and retrospective analyses, local treatment of the primary tumor in the face of metastatic disease would have an impact on survival, mainly in those patients classified as oligometastatic.

• #81 Hormone therapy for metastatic prostate cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/prostate-cancer/metastatic-cancer/treatment/hormone-therapy-for-metastatic-prostate-cancer

  Hormone therapy is a common treatment for metastatic prostate cancer. It is also called anti hormone therapy. […] Most men with metastatic prostate cancer have hormone therapy. You usually have: a combination of different hormone therapy drugs or hormone therapy with chemotherapy such as docetaxel. […] Hormone therapy with chemotherapy is often very effective at controlling metastatic prostate cancer for many months. […] There are 3 types of hormone therapy. This includes: injections, tablets, surgery. […] Surgery to remove your testicles isn’t a common way of lowering the amount of testosterone you make. […] Removing the testicles stops your body from making the hormone testosterone. It is a type of hormone therapy for prostate cancer. […] Treatment for metastatic prostate cancer can help to reduce symptoms, make you feel better and help you to live longer. Treatment includes hormone therapy, chemotherapy and radiotherapy.

• #82 Hormone therapy for metastatic prostate cancer | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/prostate-cancer/metastatic-cancer/treatment/hormone-therapy-for-metastatic-prostate-cancer

  Hormone therapy is a common treatment for metastatic prostate cancer. It is also called anti hormone therapy. […] Most men with metastatic prostate cancer have hormone therapy. You usually have: a combination of different hormone therapy drugs or hormone therapy with chemotherapy such as docetaxel. […] Hormone therapy with chemotherapy is often very effective at controlling metastatic prostate cancer for many months. […] There are 3 types of hormone therapy. This includes: injections, tablets, surgery. […] Surgery to remove your testicles isn’t a common way of lowering the amount of testosterone you make. […] Removing the testicles stops your body from making the hormone testosterone. It is a type of hormone therapy for prostate cancer. […] Treatment for metastatic prostate cancer can help to reduce symptoms, make you feel better and help you to live longer. Treatment includes hormone therapy, chemotherapy and radiotherapy.

• #83 Prostate Cancer – Advanced| Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/prostate-cancer-advanced

  Hormone therapy is frequently the first treatment offered to patients with metastatic prostate cancer. […] The more common method is androgen deprivation therapy (ADT), which uses medications to stop production of testosterone and other androgens from the testes. […] Patients who begin ADT with Lupron, Eligard or Zoladex (or Trelstar, Vantas or Viansa, which are similar drugs) will sometimes be given another testosterone-lowering drug, Casodex (bicalutamide), for two weeks at the start of therapy to counter a phenomenon known as testosterone flare that can briefly cause pain in patients who have metastases in the spine or other bones at-risk. […] We most often use intermittent ADT in patients without metastasis. In patients with metastasis, intermittent ADT therapy isn’t as effective as continuous therapy.

• #84 Prostate Cancer – Advanced| Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/prostate-cancer-advanced

  Hormone therapy is frequently the first treatment offered to patients with metastatic prostate cancer. […] The more common method is androgen deprivation therapy (ADT), which uses medications to stop production of testosterone and other androgens from the testes. […] Patients who begin ADT with Lupron, Eligard or Zoladex (or Trelstar, Vantas or Viansa, which are similar drugs) will sometimes be given another testosterone-lowering drug, Casodex (bicalutamide), for two weeks at the start of therapy to counter a phenomenon known as testosterone flare that can briefly cause pain in patients who have metastases in the spine or other bones at-risk. […] We most often use intermittent ADT in patients without metastasis. In patients with metastasis, intermittent ADT therapy isn’t as effective as continuous therapy.

• #85 Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection | Actas Urológicas Españolas (English Edition)

  https://www.elsevier.es/es-revista-actas-urologicas-espanolas-english-392-avance-resumen-recommendations-on-treatment-metastatic-hormone-sensitive-S2173578624000684

  In metastatic disease, local treatment of the primary tumor has a biological rationale, by decreasing the total tumor burden and inducing an immunogenic response that releases substances that trigger systemic anti-tumor effects (abscopal effects). […] Prostate radiotherapy should be recommended in patients with mHSPC and low tumor volume. Treatment in other subgroups should be individualized and justified by the benefits observed in the reduction of local events. […] Clinically, metastasis-directed therapy (MDT), commonly by stereotactic body radiotherapy (SBRT) has been shown to improve PFS. […] Pending the results of randomized trials, treatment with MDT (and more specifically SBRT) in oligometastatic disease seems to be an individualized option in well-informed patients and within the framework of multidisciplinary committees. […] The therapeutic landscape of mHSPC has rapidly evolved, outpacing treatment with ADT monotherapy and ADT plus docetaxel.

• #86 Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection | Actas Urológicas Españolas (English Edition)

  https://www.elsevier.es/es-revista-actas-urologicas-espanolas-english-392-avance-resumen-recommendations-on-treatment-metastatic-hormone-sensitive-S2173578624000684

  In metastatic disease, local treatment of the primary tumor has a biological rationale, by decreasing the total tumor burden and inducing an immunogenic response that releases substances that trigger systemic anti-tumor effects (abscopal effects). […] Prostate radiotherapy should be recommended in patients with mHSPC and low tumor volume. Treatment in other subgroups should be individualized and justified by the benefits observed in the reduction of local events. […] Clinically, metastasis-directed therapy (MDT), commonly by stereotactic body radiotherapy (SBRT) has been shown to improve PFS. […] Pending the results of randomized trials, treatment with MDT (and more specifically SBRT) in oligometastatic disease seems to be an individualized option in well-informed patients and within the framework of multidisciplinary committees. […] The therapeutic landscape of mHSPC has rapidly evolved, outpacing treatment with ADT monotherapy and ADT plus docetaxel.

• #87 Prostate Cancer – Advanced| Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/prostate-cancer-advanced

  In the past, the first treatment for metastatic prostate cancer was ADT alone. Other treatments would be added when the disease became ADT-resistant that is, when ADT no longer controlled the cancer. […] Unfortunately, metastatic disease typically mutates over a number of years and becomes resistant to such combination treatments. […] The three treatments commonly combined with ADT in metastatic therapy are: […] Until recently, patients who already had metastases at diagnosis weren’t offered radiation therapy or surgical removal of the prostate (prostatectomy). However, a recent randomized controlled trial has shown that for patients with a low metastatic burden, radiation treatment to the prostate can result in a significant survival benefit. […] For patients with a higher metastatic burden, no such benefit has been observed.

• #88 Prostate Cancer – Advanced| Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/prostate-cancer-advanced

  If cancer progresses despite the combination therapies described above, three additional types of therapy can be used: […] Xgeva (denosumab) is a medication used to strengthen bones. It has been shown to reduce the rate of bone injuries (such as fractures, bone pain and new bone lesions) in patients with ADT-resistant prostate cancer who have bone metastases. […] A group of medicines called bisphosphonates can also be used to prevent the loss of bone density.

• #89 Prostate Cancer – Advanced| Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/prostate-cancer-advanced

  If cancer progresses despite the combination therapies described above, three additional types of therapy can be used: […] Xgeva (denosumab) is a medication used to strengthen bones. It has been shown to reduce the rate of bone injuries (such as fractures, bone pain and new bone lesions) in patients with ADT-resistant prostate cancer who have bone metastases. […] A group of medicines called bisphosphonates can also be used to prevent the loss of bone density.

• #90 Prostate Cancer – Advanced| Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/prostate-cancer-advanced

  Hormone therapy is frequently the first treatment offered to patients with metastatic prostate cancer. […] The more common method is androgen deprivation therapy (ADT), which uses medications to stop production of testosterone and other androgens from the testes. […] Patients who begin ADT with Lupron, Eligard or Zoladex (or Trelstar, Vantas or Viansa, which are similar drugs) will sometimes be given another testosterone-lowering drug, Casodex (bicalutamide), for two weeks at the start of therapy to counter a phenomenon known as testosterone flare that can briefly cause pain in patients who have metastases in the spine or other bones at-risk. […] We most often use intermittent ADT in patients without metastasis. In patients with metastasis, intermittent ADT therapy isn’t as effective as continuous therapy.

• #91 Advanced Prostate Cancer Treatment Options

  https://www.webmd.com/prostate-cancer/treating-advanced-prostate-cancer

  The only exception to the above, is in lymph node-positive, post-prostatectomy patients, given androgen deprivation as an adjuvant immediately after surgery. In this situation, immediate therapy resulted in a significant improvement in progression free survival, prostate cancer specific survival, and overall survival. […] Researchers are pursuing several new ways to treat advanced prostate cancer. Vaccines that alter the body’s immune system and use genetically modified viruses show the most promise. […] Immune or genetic therapy have the potential to deliver more targeted, less invasive treatments for advanced prostate cancer. This would result in fewer side effects and better control of the prostate cancer.

• #92 Advanced Prostate Cancer Treatment Options

  https://www.webmd.com/prostate-cancer/treating-advanced-prostate-cancer

  The only exception to the above, is in lymph node-positive, post-prostatectomy patients, given androgen deprivation as an adjuvant immediately after surgery. In this situation, immediate therapy resulted in a significant improvement in progression free survival, prostate cancer specific survival, and overall survival. […] Researchers are pursuing several new ways to treat advanced prostate cancer. Vaccines that alter the body’s immune system and use genetically modified viruses show the most promise. […] Immune or genetic therapy have the potential to deliver more targeted, less invasive treatments for advanced prostate cancer. This would result in fewer side effects and better control of the prostate cancer.

• #93 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  If testing shows you have a gene mutation that is linked to inherited cancer risk, your blood relatives might be at higher risk, too. The Prostate Cancer Genetics Clinic at Fred Hutch can help refer your family members for genetic counseling and testing, if appropriate. We can also guide them to resources for screening and early cancer prevention. […] Research led by scientists from Fred Hutch and the University of Washington are discovering new answers. If you have prostate cancer or metastatic prostate cancer, you can receive innovative new therapies that can help you while providing valuable information that can help physicians better prevent, diagnose and treat others who develop prostate cancer. […] Patients with any stage of prostate cancer can find out if they have an inherited gene mutation by participating in The Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness (PROMISE) Study. This is important information to have since people with prostate cancer who have these mutations may have more precise treatment options and more clinical trial options.

• #94 Prostate cancer prevention: Ways to reduce your risk

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/in-depth/prostate-cancer-prevention/art-20045641

  There’s no proven prevention strategy for prostate cancer. But you may reduce your risk of prostate cancer by making healthy choices, such as exercising and eating a healthy diet. […] Researchers haven’t found a sure way to prevent prostate cancer. Study results often conflict with each other. And most studies aren’t designed to prove whether something can prevent prostate cancer. […] But healthcare professionals suggest that people with an average risk of prostate cancer make healthy lifestyle choices for prostate cancer prevention. Many of the things you can do for prostate cancer prevention are things that may help improve your health in general. […] For those with a very high risk of prostate cancer, there may be other ways to lower risk. These might include medicines. If you think you have a high risk of prostate cancer, talk with your health professional.

• #95 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The potential harms of screening, diagnostic procedures, and treatment occur soon after screening takes place. […] The USPSTF strongly encourages research on screening for and treatment of prostate cancer in African American men. […] Studies are needed to confirm that African American men who undergo screening receive similar or greater reductions in prostate cancer mortality compared with men in the general population, as well as to explore the optimal screening frequency and whether beginning screening before age 55 years provides additional benefits in African American men. […] The USPSTF does not recommend screening for prostate cancer in men, including African American men, older than 70 years. […] The USPSTF believes that a reasonable approach for clinicians is to inform men with a family history of prostate cancer, particularly those with multiple first-degree relatives with prostate cancer, about their increased risk of developing cancer as well as the potential earlier age at disease onset. […] The USPSTF does not recommend screening for prostate cancer in men, including men with a family history of prostate cancer, older than 70 years.

• #96 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The potential harms of screening, diagnostic procedures, and treatment occur soon after screening takes place. […] The USPSTF strongly encourages research on screening for and treatment of prostate cancer in African American men. […] Studies are needed to confirm that African American men who undergo screening receive similar or greater reductions in prostate cancer mortality compared with men in the general population, as well as to explore the optimal screening frequency and whether beginning screening before age 55 years provides additional benefits in African American men. […] The USPSTF does not recommend screening for prostate cancer in men, including African American men, older than 70 years. […] The USPSTF believes that a reasonable approach for clinicians is to inform men with a family history of prostate cancer, particularly those with multiple first-degree relatives with prostate cancer, about their increased risk of developing cancer as well as the potential earlier age at disease onset. […] The USPSTF does not recommend screening for prostate cancer in men, including men with a family history of prostate cancer, older than 70 years.

• #97 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The potential harms of screening, diagnostic procedures, and treatment occur soon after screening takes place. […] The USPSTF strongly encourages research on screening for and treatment of prostate cancer in African American men. […] Studies are needed to confirm that African American men who undergo screening receive similar or greater reductions in prostate cancer mortality compared with men in the general population, as well as to explore the optimal screening frequency and whether beginning screening before age 55 years provides additional benefits in African American men. […] The USPSTF does not recommend screening for prostate cancer in men, including African American men, older than 70 years. […] The USPSTF believes that a reasonable approach for clinicians is to inform men with a family history of prostate cancer, particularly those with multiple first-degree relatives with prostate cancer, about their increased risk of developing cancer as well as the potential earlier age at disease onset. […] The USPSTF does not recommend screening for prostate cancer in men, including men with a family history of prostate cancer, older than 70 years.

• #98 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce

  https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

  The goal of screening for prostate cancer is to identify high-risk, localized prostate cancer that can be successfully treated, thereby preventing the morbidity and mortality associated with advanced or metastatic prostate cancer. […] Adequate evidence from randomized clinical trials (RCTs) shows that PSA-based screening programs in men aged 55 to 69 years may prevent approximately 1.3 deaths from prostate cancer over approximately 13 years per 1000 men screened. […] Screening programs may also prevent approximately 3 cases of metastatic prostate cancer per 1000 men screened. […] The USPSTF concludes with moderate certainty that the potential benefits of PSA-based screening for prostate cancer in men 70 years and older do not outweigh the expected harms. […] The USPSTF does not recommend screening for prostate cancer unless men express a preference for screening after being informed of and understanding the benefits and risks.

• #99 Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection | Actas Urológicas Españolas (English Edition)

  https://www.elsevier.es/es-revista-actas-urologicas-espanolas-english-392-avance-resumen-recommendations-on-treatment-metastatic-hormone-sensitive-S2173578624000684

  In metastatic disease, local treatment of the primary tumor has a biological rationale, by decreasing the total tumor burden and inducing an immunogenic response that releases substances that trigger systemic anti-tumor effects (abscopal effects). […] Prostate radiotherapy should be recommended in patients with mHSPC and low tumor volume. Treatment in other subgroups should be individualized and justified by the benefits observed in the reduction of local events. […] Clinically, metastasis-directed therapy (MDT), commonly by stereotactic body radiotherapy (SBRT) has been shown to improve PFS. […] Pending the results of randomized trials, treatment with MDT (and more specifically SBRT) in oligometastatic disease seems to be an individualized option in well-informed patients and within the framework of multidisciplinary committees. […] The therapeutic landscape of mHSPC has rapidly evolved, outpacing treatment with ADT monotherapy and ADT plus docetaxel.

• #100 Prostate Cancer | Huntsman Cancer Institute | University of Utah Health

  https://healthcare.utah.edu/huntsmancancerinstitute/urologic-cancer/prostate-cancer

  We also have a portfolio of therapeutic options outside of standard care, and our clinical care delivery is unparalleled. Our multidisciplinary tumor boards consult on every patient case, looking at imaging, making sure all therapeutic portfolios are considered, and leaving no stone unturned for treatment. […] Additionally, we offer a Prostate Cancer Risk Clinic for men at increased risk due to genetic factors or family history, providing personalized screening and prevention strategies. […] We continue to be at the forefront of prostate cancer research, focusing on developing novel treatments and improving patient outcomes. […] A notable achievement is our TALAPRO-2 trial, which demonstrated that a combination of enzalutamide and talazoparib significantly improves overall survival rates in patients with metastatic prostate cancer compared to standard therapy. […] Learn more about ways to prevent cancer and about cancer screenings.

• #101 Prostate Cancer | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/prostate-cancer.html

  Metastatic prostate cancer is prostate cancer that has spread outside of the prostate to other parts of the body. This is also known as stage IV disease. […] We work together as a team of specialists to treat stage IV prostate cancer. Patients may receive: Hormone therapy, Chemotherapy, Radiation therapy, Supportive care. […] The average length of survival after a new, metastatic prostate cancer diagnosis is about 5 to 6 years. […] If a patient’s prostate cancer has spread beyond the prostate and the surrounding area, he is given systemic therapies like hormone therapy and possibly chemotherapy. While cancer responds to hormone therapy, it is called castrate-sensitive disease. Over time, the disease may become less responsive to hormone therapy and start growing again. This is called castrate-resistant disease. Patients with castrate-resistant disease can be treated with a number of additional therapies. Many are eligible for clinical trials with newer drugs or drug combinations, including immunotherapy.

• #102 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  A genetic counselor can also determine if genetic testing could be helpful for you, based on your personal and family medical and health history. After you have had genetic testing, a genetic counselor can offer information about cancer screening options and steps you can take to help prevent cancer, based on your results.

• #103 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  A genetic counselor can also determine if genetic testing could be helpful for you, based on your personal and family medical and health history. After you have had genetic testing, a genetic counselor can offer information about cancer screening options and steps you can take to help prevent cancer, based on your results.

• #104 Prostate Cancer: Current Treatment and Prevention Strategies

  https://pmc.ncbi.nlm.nih.gov/articles/PMC3785898/

  Prostate cancer is one of the life threatening disorders of male. […] Current medical treatment approaches include surgery, radiation therapy, chemotherapy, hormonal therapy, cryosurgery and other methods. […] Dietary modifications may also contribute to decrease prostate cancer risk. […] This review article summarizes some of the current treatment, and prevention strategies with the protection of prostate cancer, which may be helpful to control and prevent this highly frequent life threatening disease. […] Dietary management, and other lifestyle modification of patients with prostate cancer have also shown some positive results to control, and prevent prostate cancer. […] Proper dietary management may keep away a person from prostate cancer risk.

• #105 Prostate cancer prevention: Ways to reduce your risk

  https://www.mayoclinic.org/diseases-conditions/prostate-cancer/in-depth/prostate-cancer-prevention/art-20045641

  There’s no proven prevention strategy for prostate cancer. But you may reduce your risk of prostate cancer by making healthy choices, such as exercising and eating a healthy diet. […] Researchers haven’t found a sure way to prevent prostate cancer. Study results often conflict with each other. And most studies aren’t designed to prove whether something can prevent prostate cancer. […] But healthcare professionals suggest that people with an average risk of prostate cancer make healthy lifestyle choices for prostate cancer prevention. Many of the things you can do for prostate cancer prevention are things that may help improve your health in general. […] For those with a very high risk of prostate cancer, there may be other ways to lower risk. These might include medicines. If you think you have a high risk of prostate cancer, talk with your health professional.

• #106 What lifestyle changes can help me avoid prostate cancer? – Harvard Health

  https://www.health.harvard.edu/mens-health/what-lifestyle-changes-can-help-me-avoid-prostate-cancer

  If men live long enough, most will develop cancer cells in their prostate gland. About 80% of men ages 80 and older live with some prostate cancer. […] Therefore, the more important questions are what lifestyle changes might delay the onset of prostate cancer and decrease the risk of developing advanced prostate cancer. Here are three areas that observational studies have found may help. […] Research has shown that the same types of diets associated with better heart and brain health are linked to a reduced risk of aggressive prostate cancer. In a study published in the March 2022 issue of The American Journal of Clinical Nutrition, researchers who followed 47,239 men over 28 years found that men who reported eating primarily a plant-based diet, like the Mediterranean or DASH diets, had a significantly lower risk of developing aggressive prostate cancer.

• #107 Prostate Cancer Prevention (PDQ®) – PDQ Cancer Information Summaries – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK65968/

  Chemoprevention with finasteride and dutasteride reduces the incidence of prostate cancer, but the evidence is inadequate to determine whether chemoprevention with finasteride or dutasteride reduces mortality from prostate cancer. […] In the Prostate Cancer Prevention Trial (PCPT), absolute reduction in incidence for more than 7 years with finasteride as compared with placebo was 6% (18.4% with finasteride and 24.4% with placebo); relative risk reduction (RRR) for incidence was 24.8% (95% confidence interval [CI], 18.6%30.6%). […] The Oncology Drugs Advisory Committee of the FDA examined both finasteride and dutasteride in 2010. Neither agent was recommended for use for chemoprevention of prostate cancer. […] The Selenium and Vitamin E Cancer Prevention Trial (SELECT [NCT00006392]) was a large randomized placebo-controlled trial of vitamin E and selenium. It showed no reduction in prostate cancer period prevalence, but an increased risk of prostate cancer with vitamin E alone.

• #108 Pluvicto for Metastatic Prostate Cancer | The University of Kansas Cancer Center

  https://www.kucancercenter.org/cancer/cancer-treatments/pluvicto

  The University of Kansas Cancer Center is the first and only cancer center in the region to offer an innovative prostate cancer treatment for men with metastatic prostate cancer. […] Pluvicto is a new targeted therapy for metastatic prostate cancer. […] While Pluvicto is not a cure for metastatic prostate cancer, it can give you a longer life and improved quality of life with reduced side effects. […] Pluvicto is a new targeted therapy for metastatic prostate cancer that delivers radiation treatment directly to prostate-specific membrane antigen or PSMA-positive cancer cells. […] To receive Pluvicto, you must have metastatic prostate cancer that is hormone-resistant and tumors that overproduce the PSMA protein. […] Pluvicto is not a cure for metastatic prostate cancer, but it can give you a longer life and improved quality of life with reduced side effects.

• #109 Attacking metastatic prostate cancer early with combination treatment approach improves outcomes in preliminary study | UCLA Health

  https://www.uclahealth.org/news/release/attacking-metastatic-prostate-cancer-early-with-combination

  A team of UCLA Health Jonsson Comprehensive Cancer Center investigators has shown the combination of a short course of powerful and intense hormonal therapy with targeted radiation is safe and effective in treating people with prostate cancer that has come back and has spread to other parts of the body. […] These results suggest a substantial improvement and strongly suggest there can be a meaningful impact namely, delaying the need for hormonal therapy and thus without the significant side effects of it by attacking metastatic prostate cancer early. […] One way to prolong the use of hormonal therapy while controlling PSA levels is to leverage a combination of therapies, including stereotactic body radiation therapy (SBRT), which delivers highly focused and intense doses of radiation to the tumor while minimizing exposure to surrounding healthy tissues in short duration. […] The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen.

• #110 Advanced Prostate Cancer Treatment Options

  https://www.webmd.com/prostate-cancer/treating-advanced-prostate-cancer

  Prostate cancer occurs when a tumor develops in the prostate gland, which makes the liquid portion of semen. Cancer that spreads outside the prostate gland to the lymph nodes, bones, or other areas is called metastatic prostate cancer. Currently, no treatments can cure advanced prostate cancer. However, there are ways to help control its spread and related symptoms. […] It’s important to remember that researchers are always searching for new and better treatments that will cause fewer side effects, better disease control, and longer survival rates. […] Hormone (endocrine) therapy, known as androgen ablation or androgen suppression therapy, is the main treatment for advanced prostate cancer. It is the first line of treatment for metastatic prostate cancer. […] Most doctors agree that hormone therapy is the most effective treatment available for patients with advanced prostate cancer. However, there is disagreement on exactly how and when hormone therapy should be used.

• #111 Prostate Cancer | Huntsman Cancer Institute | University of Utah Health

  https://healthcare.utah.edu/huntsmancancerinstitute/urologic-cancer/prostate-cancer

  We also have a portfolio of therapeutic options outside of standard care, and our clinical care delivery is unparalleled. Our multidisciplinary tumor boards consult on every patient case, looking at imaging, making sure all therapeutic portfolios are considered, and leaving no stone unturned for treatment. […] Additionally, we offer a Prostate Cancer Risk Clinic for men at increased risk due to genetic factors or family history, providing personalized screening and prevention strategies. […] We continue to be at the forefront of prostate cancer research, focusing on developing novel treatments and improving patient outcomes. […] A notable achievement is our TALAPRO-2 trial, which demonstrated that a combination of enzalutamide and talazoparib significantly improves overall survival rates in patients with metastatic prostate cancer compared to standard therapy. […] Learn more about ways to prevent cancer and about cancer screenings.

• #112 Prostate Cancer Genetics Clinic | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/patient-care/prevention/prostate-cancer-genetics.html

  A genetic counselor can also determine if genetic testing could be helpful for you, based on your personal and family medical and health history. After you have had genetic testing, a genetic counselor can offer information about cancer screening options and steps you can take to help prevent cancer, based on your results.

Zobacz więcej